Player is loading...
elthera
Wednesday, Oct. 25, 2017 · 11:12 a.m. · 03m 55s
Embed
Transcriptions
Note: this content has been automatically generated.
00:00:00
is orders that the remote uh_huh go scary
00:00:09
oh
00:00:12
i i'm an and the seal of it yeah i mean we are
00:00:15
developing an antibody against the run cam for the treatment of cancer
00:00:20
so l. ones cell adhesion molecule is expressed on many to most but the
00:00:25
highest numbers in pancreatic and ovarian cancer
00:00:29
our first to a target indications
00:00:33
the expression of that one can is always correlated
00:00:37
with the poor prognosis for the patients
00:00:40
because no one can has multiple roles into war progressions soul
00:00:44
it probably won't to what growth and the test this is formation directly
00:00:49
it contributes to the formation off new plot
00:00:52
vessels supplying the tomorrow bit nutrients
00:00:57
it also looking chooses resistance to chemotherapy
00:01:01
and it blocks the immune system from fighting the cancer and
00:01:07
looking at this as solution becomes immediately abbott and so
00:01:12
when court identified the patients bit than a one can positive to more
00:01:18
but the suitable companion diagnostic and then treat these patients but an
00:01:24
antibody that blocks and one came and this should revert
00:01:28
the functions of everyone came and he too with therapeutic benefit
00:01:34
and in fact our um licensing partners at the
00:01:39
german cancer research centre have already demonstrated
00:01:44
preclinical proof of concept in mouse models some nice treat that
00:01:49
with anti open can antibodies show to reduce to memorise
00:01:53
and the prolonged survival soul school of course i mean
00:02:00
such another treatment would have a huge market potential
00:02:04
and our compound has blockbuster potential already in the first two indications
00:02:11
we are an experienced team but more than
00:02:15
fifty years of experience in bringing
00:02:19
biological compounds from early research into clinical development
00:02:24
and also very important to know that we can work to get up because
00:02:28
we have done in the past in the management team of s. partake
00:02:33
we have successfully close to see a round in some of these year and have started our activities
00:02:40
and we're not gonna see you round yeah we are looking for two million
00:02:44
swiss francs to select our clinical candidate molecule if this is interested oh
00:02:51
condor night we are around all day and we'll still have slots in our our meeting schedule
00:02:58
right a regular high crime
00:03:04
but uh i one one question is there anybody with a
00:03:07
question school question i have one of the competition
00:03:12
actually to our surprise there is no competition really so there's
00:03:16
no other uh i attack of from our company
00:03:21
uh developing an antibody against the one can however it is to not therapeutics well also things that
00:03:27
one can is a is a valuable target and they're developing a cart to you um therapy
00:03:34
for the treatment of new applies to my patients are going to remote thanks again on it so now please please
Conference Program
certus diagnostics
Oct. 25, 2017 · 11:29 a.m.
224 views
Trackcath?
Oct. 25, 2017 · 11:32 a.m.
Ophtho robotics
Oct. 25, 2017 · 11:45 a.m.
234 views
FlavorWiki
Oct. 25, 2017 · 12:09 p.m.
367 views
Farmerline
Oct. 25, 2017 · 12:21 p.m.
104 views
